Clinical Trial Detail

NCT ID NCT03632941
Title A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Herbert Lyerly
Indications

breast cancer

Therapies

Pembrolizumab

AVX901 + Pembrolizumab

AVX901

Age Groups: adult senior

No variant requirements are available.